

# Vincenza Calvaruso

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2532054/vincenza-calvaruso-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

121  
papers

3,917  
citations

35  
h-index

59  
g-index

166  
ext. papers

4,755  
ext. citations

4.2  
avg, IF

5.05  
L-index

#	Paper	IF	Citations
121	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.. <i>Liver Cancer</i> , <b>2022</b> , 11, 75-84	9.1	4
120	Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1301-1307	3.3	2
119	Reply to: "Hepatic benefits of HCV cure: Don't forget coagulation!". <i>Journal of Hepatology</i> , <b>2021</b> , 74, 969	13.4	
118	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. <i>JHEP Reports</i> , <b>2021</b> , 3, 100248	10.3	10
117	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1603-1609	3.3	
116	Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1190-1199	3.4	3
115	Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Native Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach. <i>Hepatology</i> , <b>2021</b> , 74, 1496-1508	11.2	4
114	Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals. <i>Liver International</i> , <b>2021</b> , 41, 2179-2188	7.9	1
113	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 801-810	13.4	12
112	Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1109-1116	13.4	39
111	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 340-349	13.4	11
110	Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. <i>Liver International</i> , <b>2021</b> , 41, 1802-1814	7.9	8
109	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 572-581	13.4	8
108	Development or worsening of esophageal varices in patients with cirrhosis after DAA-induced HCV clearance. <i>Journal of Hepatology</i> , <b>2020</b> , 73, S625-S626	13.4	
107	P114 A screening tool for the early diagnosis of extraintestinal manifestations in inflammatory bowel disease: the EMAIL questionnaire. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S192-S193	1.5	
106	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. <i>Atherosclerosis</i> , <b>2020</b> , 296, 40-47	3.1	36
105	Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy. <i>Liver International</i> , <b>2020</b> , 40, 530-538	7.9	1

104	P228 Cytomegalovirus Infection: is it a cause of flare-up in inflammatory bowel diseases?. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S256-S257	1.5	
103	P293 Loss of response after first-line biologic therapy in patients with inflammatory bowel disease: practical approach and management. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S299-S299	1.5	
102	Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis. <i>Liver International</i> , <b>2020</b> , 40, 2820-2827	7.9	9
101	Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2408-2416	6.7	28
100	Hepatic benefits of HCV cure. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1548-1556	13.4	22
99	Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study). <i>Liver International</i> , <b>2019</b> , 39, 2240-2243	7.9	3
98	Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. <i>Scientific Reports</i> , <b>2019</b> , 9, 585	4.9	6
97	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 265-273	13.4	80
96	P522 Expression of markers of early atherosclerosis in inflammatory bowel disease: a prospective cohort of a single referral centre. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S373-S374	1.5	
95	Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 1275-1282	0.7	23
94	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , <b>2019</b> , 17, 117-128	5.3	5
93	Predictors of Re-bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic Shunt (TIPS). <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 1335-1345	4	29
92	Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 310-317	3.3	29
91	Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients. <i>Infection</i> , <b>2019</b> , 47, 409-415	5.8	3
90	Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B e-antigen-negative chronic hepatitis B genotype D. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 118-125	3.4	11
89	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 18-24	13.4	68
88	HCV-FiS (HEpatitis C Virus Finger-stick Study): HCV RNA point-of-care testing by GeneXpert in the setting of DAA therapy. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 58	3.3	
87	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , <b>2018</b> , 155, 411-421.e4	13.3	201

86	Is global elimination of HCV realistic?. <i>Liver International</i> , <b>2018</b> , 38 Suppl 1, 40-46	7.9	30
85	High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1705-1712 <sup>21</sup>	6.1	21
84	HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 72-79	3.4	33
83	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 597-600	13.4	23
82	Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study. <i>Clinical Transplantation</i> , <b>2018</b> , 32, e13165	3.8	9
81	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 878-885	13.4	75
80	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , <b>2018</b> , 391, 2417-2429	40	176
79	Disease outcomes after DAA-induced SVR: data from the resist-HCV cohort. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S83	13.4	4
78	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , <b>2017</b> , 37, 514-528	7.9	71
77	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 731-741	3.3	14
76	Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. <i>Liver International</i> , <b>2017</b> , 37, 1526-1534	7.9	29
75	Occurrence of hepatocellular carcinoma in patients with hepatitis C virus related liver disease treated with direct-acting antivirals. <i>Journal of Hepatology</i> , <b>2017</b> , 66, S23-S24	13.4	3
74	Hepatocellular carcinoma and direct-acting antivirals: A never ending story?. <i>Liver International</i> , <b>2017</b> , 37, 812-814	7.9	2
73	Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs). <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, e60	3.3	3
72	Risk of hepatocellular carcinoma (HCC) recurrence in HCV cirrhotic patients treated with Direct Acting Antivirals (DAAs). <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, e59	3.3	2
71	Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. <i>PLoS ONE</i> , <b>2017</b> , 12, e0177352	3.7	11
70	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 427-434	18.8	13
69	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 688-695	6.1	104

68	Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 485-493	13.4	160
67	Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 37, 83-89	3.9	22
66	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185728	3.7	28
65	A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort. <i>European Review for Medical and Pharmacological Sciences</i> , <b>2017</b> , 21, 112-121	2.9	25
64	AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 860-8	3.3	14
63	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 739-50	5.1	12
62	Why do I treat my patients with mild hepatitis C?. <i>Liver International</i> , <b>2016</b> , 36 Suppl 1, 7-12	7.9	19
61	AISF position paper on liver disease and pregnancy. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 120-37	3.3	23
60	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 455-467	3.3	41
59	Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 650-5	3.3	6
58	Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. <i>Liver International</i> , <b>2016</b> , 36, 1765-1773	7.9	14
57	Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. <i>Gastroenterology</i> , <b>2016</b> , 151, 130-139.e2	13.3	107
56	Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 1217-23	13.4	84
55	Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 477-86	6.1	12
54	Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. <i>DMM Disease Models and Mechanisms</i> , <b>2015</b> , 8, 1037-46	4.1	42
53	Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. <i>Future Microbiology</i> , <b>2015</b> , 10, 977-88	2.9	2
52	Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22, 469-80	3.4	6
51	Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis. <i>Analytical Cellular Pathology</i> , <b>2015</b> , 2015, 431750	3.4	13

50	Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. <i>Pathobiology</i> , <b>2015</b> , 82, 48-52	3.6	8
49	Clinical implications of the hyperdynamic syndrome in cirrhosis. <i>European Journal of Internal Medicine</i> , <b>2014</b> , 25, 795-802	3.9	33
48	An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 818-25	3.3	8
47	Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?. <i>Liver International</i> , <b>2014</b> , 34 Suppl 1, 85-90	7.9	47
46	Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 16-21	13.4	23
45	Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. <i>PLoS ONE</i> , <b>2014</b> , 9, e110857	3.7	13
44	The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis. <i>Journal of Gastroenterology</i> , <b>2013</b> , 48, 921-9	6.9	32
43	Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 867-74	3.4	67
42	Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 962-8	13.4	48
41	Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 113-21	3.4	16
40	Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance. <i>Hepatitis Monthly</i> , <b>2013</b> , 13, e7176	1.8	10
39	Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 790-800	3.4	10
38	NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis. <i>PLoS ONE</i> , <b>2013</b> , 8, e68364	3.7	20
37	Immunological alterations in hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 8916-23	5.6	22
36	Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2012</b> , 27, 1227-32	4	50
35	IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. <i>Haematologica</i> , <b>2012</b> , 97, 679-86	6.6	41
34	2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. <i>Liver International</i> , <b>2012</b> , 32 Suppl 1, 2-8	7.9	83
33	Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea. <i>Journal of Clinical Gastroenterology</i> , <b>2012</b> , 46, 504-8	3	25

32	Extrahepatic Manifestations of Chronic HCV <b>2012</b> , 61-73		
31	Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 2112-20	0.7	148
30	Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. <i>Liver International</i> , <b>2011</b> , 31, 730-9	7.9	92
29	Fibrosis in chronic viral hepatitis. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2011</b> , 25, 219-30	2.5	20
28	Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation. <i>Liver Transplantation</i> , <b>2011</b> , 17, 178-88	4.5	62
27	Pegylated-interferon-(2a) in clinical practice: how to manage patients suffering from side effects. <i>Expert Opinion on Drug Safety</i> , <b>2011</b> , 10, 429-35	4.1	15
26	Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with <sup>51</sup> Cr-EDTA clearance in patients with cirrhosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2011</b> , 6, 84-92	6.9	51
25	Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis. <i>Gut</i> , <b>2011</b> , 60, 1023	19.2	9
24	A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation. <i>Journal of Viral Hepatitis</i> , <b>2010</b> , 17, 640-9	3.4	22
23	Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. <i>British Journal of Haematology</i> , <b>2010</b> , 148, 476-9	4.5	45
22	Hepassocin as a treatment for fulminant hepatic failure: will it translate from rats to human?. <i>Gut</i> , <b>2010</b> , 59, 709-10	19.2	4
21	Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 143-8	3.3	23
20	Prospective comparison of Fibroscan, KingQ score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection. <i>Journal of Viral Hepatitis</i> , <b>2010</b> , 17, 546-54	3.4	39
19	Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy. <i>Journal of Viral Hepatitis</i> , <b>2010</b> , 17, 469-74	3.4	23
18	PTU-059 Which correlation among histological assessment of fibrosis, non-invasive markers and portal hypertension in HCV transplanted patients?. <i>Gut</i> , <b>2010</b> , 59, A72.2-A73	19.2	
17	Histological subclassification of cirrhosis. <i>Hepatology</i> , <b>2010</b> , 52, 804-5	11.2	9
16	Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. <i>Journal of Thrombosis and Haemostasis</i> , <b>2010</b> , 8, 1994-2000	15.4	145
15	Critically ill patients with cirrhosis and low serum sodium. <i>Journal of Clinical Gastroenterology</i> , <b>2010</b> , 44, 523-4; author reply 524-5	3	3

14	Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. <i>Hepatology</i> , <b>2009</b> , 49, 1236-44	11.2	202
13	Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 603-13	6.1	20
12	An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers. <i>Journal of Viral Hepatitis</i> , <b>2009</b> , 16, 769-74	3.4	37
11	Implication of normal liver enzymes in liver disease. <i>Journal of Viral Hepatitis</i> , <b>2009</b> , 16, 529-36	3.4	34
10	RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2009</b> , 24, 1639-47	4	79
9	Impact of tips preliver transplantation for the outcome posttransplantation. <i>American Journal of Transplantation</i> , <b>2009</b> , 9, 192-200	8.7	46
8	Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. <i>Journal of Viral Hepatitis</i> , <b>2008</b> , 15, 699-709	3.4	88
7	Muscle cramps in cirrhosis: the therapeutic value of quinine. Is it underused?. <i>Digestive and Liver Disease</i> , <b>2008</b> , 40, 794-9	3.3	13
6	Coagulation and fibrosis in chronic liver disease. <i>Gut</i> , <b>2008</b> , 57, 1722-7	19.2	47
5	TACE versus TAE as therapy for hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2008</b> , 8, 1623-41	3.5	65
4	Models for non-alcoholic fatty liver disease: a link with vascular risk. <i>Current Pharmaceutical Design</i> , <b>2008</b> , 14, 378-84	3.3	8
3	Thrombin Generation Is Normal in Most Patients with Cirrhosis despite a Prolonged INR.. <i>Blood</i> , <b>2008</b> , 112, 1826-1826	2.2	
2	Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. <i>Journal of Hepatology</i> , <b>2007</b> , 47, 484-91	13.4	84
1	Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 6861-4	5.6	8